Medtronic (NYSE:MDT – Free Report) had its price objective lifted by Wells Fargo & Company from $102.00 to $105.00 in a research note issued to investors on Friday, Benzinga reports. They currently have an overweight rating on the medical technology company’s stock. A number of other equities research analysts also recently issued reports on the […]

Related Keywords

Canada , Michael Marinaro , Needham Company , Royal Bank , Morgan Stanley , Wells Fargo Company , Norges Bank , York Mellon Corp , Capital Research Global Investors , Medtronic , Northern Trust Corp , Medtronic Company Profile , Free Report , Wells Fargo , Truist Financial , Get Free Report , Research Global Investors , New York Mellon Corp , Trust Corp , Cardiovascular Portfolio , Medtronic Daily ,